Abstract
We demonstrate low rates of breakthrough coronavirus disease 2019 (COVID-19) infection and mild course of illness following severe acute respiratory syndrome coronavirus 2 vaccination in a large cohort of inflammatory bowel disease patients. Residence in southern United States and lower median anti-receptor binding antibody level were associated with development of COVID-19.
Original language | English (US) |
---|---|
Pages (from-to) | 483-486 |
Number of pages | 4 |
Journal | Inflammatory bowel diseases |
Volume | 29 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1 2023 |
Funding
This research was funded by the Leona M. and Harry B. Helmsley Charitable Trust. R.C.U. is funded by a National Institutes of Health Career Development Award (K23KD111995-01A1).
ASJC Scopus subject areas
- Immunology and Allergy
- Gastroenterology